Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP

Journal of Infectious Diseases

Volumn 192, Issue 1, 2005, Pages 30-36

  Eshleman, Susan H ^a   Hoover, Donald R ^c   Chen, Shu ^b   Hudelson, Sarah E ^a   Guay, Laura A ^a   Mwatha, Anthony ^d   Fiscus, Susan A ^e   Mmiro, Francis ^f   Musoke, Philippe ^f   Jackson, J Brooks ^a   Kumwenda, Newton ^b   Taha, Taha ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; ZIDOVUDINE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MUTATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRUS LOAD; VIRUS TYPING;

ADULT; ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; NEVIRAPINE; PREGNANCY; VIRAL PROTEINS;

EID: 20844453585     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/430764     Document Type: Article

References (30)

1. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda: HIVNET-012 randomised trial. Lancet 1999; 354:795-802.
2. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 months follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362:859-68.
3. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187:725-35.
4. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intra-partum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002; 288: 189-98.
5. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217-28.
6. Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevirapine (NVP) resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single dose NVP (HIVNET 012). J Acquir Immune Defic Syndr 2004; 35:126-30.
7. Kantor R, Lee E, Johnston E, et al. Rapid flux in non-nucleoside reverse transcriptase mutations among subtype C HIV-1-infected women after single dose nevirapine. Antivir Ther 2003; 8:S85.
8. Cunningham CK, Chaix M-L, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of Pediatric AIDS Clinical Trials Group Protocol 316. J Infect Dis 2002; 186:181-8.
9. Gordon M, Graham N, Bland D, et al. Surveillance of resistance in KZN South Africa, including mother-infant pairs 6 weeks after single-dose NVP. Antivir Ther 2004; 9:S80.
10. Chaix ML, Ekouevi DK, Peytavin G, et al. Persistance of nevirapine-resistant virus and pharmacokinetic analysis in women who received intrapartum NVP associated to a short course of zidovudine (ZDV) to prevent perinatal HIV-1 transmission: the Ditrame plus ANRS 1201/02 Study, Abidjan, Cote d'Ivoire. Antivir Ther 2004; 9:S176.
11. Martinson N, Morris L, Gray G, et al. HIV resistance and transmission following single-dose nevirapine in a PMTCT cohort [abstract 38]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco, CA, 2004). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004:91.
12. Ngo-Giang-Huong N, Tungyai P, Kummee A, et al. Profile of NNRTI associated mutations in women exposed to a single dose of nevirapine during delivery in Thailand [abstract WeOrB1289]. In: Program and abstracts of the 15th International AIDS Conference (Bangkok, Thailand, 2004). Geneva: International AIDS Society, 2004.
13. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998; 178:368-74.
14. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13:479-86.
15. Muro E, Droste I, Hofstede H, Bosch M, Dolmans W, Burger D. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose NVP: implications for intervention studies [abstract 891]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco, CA, 2004). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004:397.
16. Jackson JB, Becker-Pergola G, Guay L, et al. Identification of the K103N mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14:F111-5.
17. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al, Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351:229-40.
18. Eshleman SH, Becker-Pergola G, Deseyve M, et al. Impact of HIV-1 subtype on women receiving single dose NVP prophylaxis to prevent HIV-1 vertical transmission (HP/NET 012). J Infect Dis 2001; 184:914-7.
19. Taha TE, Kumwenda NI, Hoover DR, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004; 292:202-9.
20. Siepel AC, Halpern AL, Macken C, Korber BT. A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences. AIDS Res Hum Retroviruses 1995; 11:1413-6.
21. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003; 17:F1-5.
22. Kantor R, Carvalho AP, Wynhoven B, et al. Nucleic acid differences between HIV-1 non-B and B reverse transcriptase and protease sequences at drug resistance positions. Antivir Ther 2003; 8:S58.
23. Dumans AT, Soares MA, Machado ES, et al. Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus type 1 subtypes may influence mutational routes to drug resistance. J Infect Dis 2004; 189:1232-8.
24. Abecasis A, Gomes P, Derdelinckx I, et al. L89I/V: a novel mutation selected by protease inhibitor therapy in subtype G, but not in subtype B-infected patients. Antivir Ther 2003; 8:S140.
25. Eshleman SH, Wang J, Guay LA, et al. Distinct patterns of selection and fading of K103N and Y181C are seen in women with subtype A vs. D HIV-1 after single dose nevirapine: HIVNET 012. Antivir Ther 2004; 9:S59.
26. Morris L, Martinson N, Pillay C, et al. Persistence of nevirapine resistance mutations 6 months following single dose nevirapine [abstract ThOrB1353]. In: Program and abstracts of the 15th International AIDS Conference (Bangkok, Thailand, 2004). Geneva: International AIDS Society, 2004.
27. Eshleman SH, Nissley D, Claasen C, et al. Sensitive drug resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine-resistance mutation in some women and infants after single the 12th Conference on Retroviruses and Opportunistic Infections (Boston, MA, 2005). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005:360.
28. Johnson J, Li JF, Morris L, et al. Resistance emerges in the majority of women provided intrapartum single-dose nevirapine [abstract 100]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston, MA, 2005). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005:101.
29. Palmer S, Boltz V, Maldarelli F, et al. Persistence of NNRTI-resistant variants after single-dose nevirapine in HIV-1 subtype C-infected women [abstract 101]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston, MA, 2005). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005:101.
30. Loubser S, Balfe P, Sherman G, et al. Sensitive real-time PCR quantification of 103N resistance mutants following single-dose treatment with nevirapine [abstract 102]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston, MA, 2005). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005:102.